A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
- Conditions
- Myocardial InfarctionCoronary Disease
- Registration Number
- NCT00060554
- Lead Sponsor
- Schering-Plough
- Brief Summary
The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- 300
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (26)
Ocala Research Institute, Inc.
🇺🇸Ocala, Florida, United States
University of Chicago - Section of Cardiology
🇺🇸Chicago, Illinois, United States
UMass Memorial Medical Center
🇺🇸Worcester, Massachusetts, United States
University of Michigan, Dept. of Internal Medicine
🇺🇸Ann Arbor, Michigan, United States
Greenville Hospital System
🇺🇸Greenville, South Carolina, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
The Methodist Hospital
🇺🇸Houston, Texas, United States
University of Virginia Health System
🇺🇸Charlottesville, Virginia, United States
Foothills Hospital
🇨🇦Calgary, Alberta, Canada
University of Alberta Hospital
🇨🇦Edmonton, Alberta, Canada
Scroll for more (16 remaining)Ocala Research Institute, Inc.🇺🇸Ocala, Florida, United States